Boston Scientific Corp. (NYSE: BSX) in Natick has announced that its Watchman Left Atrial Appendage (LAA) closure device has an expanded indication in Europe, and now has been approved to reduce strokes in patients with atrial fibrillation (AF), and who cannot use warfarin and the newer oral blood thinners.